TERREMOTO BIOSCIENCES, INC. – Trademark Portfolio
Entity Type: 03
TERREMOTO BIOSCIENCES, INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 3 are pending. Notable registered marks include TERREMOTO and TERREMOTO BIOSCIENCES. The owner is based in South San Francisco, CA.
230 East Grand Avenue, Suite 200
South San Francisco, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
TERREMOTO BIOSCIENCES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does TERREMOTO BIOSCIENCES, INC. have?
TERREMOTO BIOSCIENCES, INC. has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 pending.
What trademark classes does TERREMOTO BIOSCIENCES, INC. file in?
TERREMOTO BIOSCIENCES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are TERREMOTO BIOSCIENCES, INC.'s most well-known trademarks?
TERREMOTO BIOSCIENCES, INC.'s registered trademark portfolio includes well-known marks such as TERREMOTO and TERREMOTO BIOSCIENCES. These are among 2 currently registered trademarks in the portfolio.
What is TERREMOTO BIOSCIENCES, INC.'s trademark registration success rate?
TERREMOTO BIOSCIENCES, INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 3 applications are pending review.